Dyne Therapeutics, Inc. - 10-Q Filing

Dyne Therapeutics reported its Q2 financial results and provided updates on marketable securities, loan agreements, and stock incentive plans.

SEC EDGAR ·

Tickers: $DYN

Read the full article at SEC EDGAR

More Regulatory news